Standard Contracts
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into this 26th day of July 2006 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 25th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 2nd day of October 2009 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 8th day of July, 2009 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation, having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 21 day of December 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Hørsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred to herein individually as a “Party” or collectively, as the “Parties”.
AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 9th, 2012 • Enzon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 9th, 2012 Company Industry JurisdictionTHIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), is entered into this 13th day of June 2007 (the “Effective Date”) by and between Santaris Pharma A/S, a Danish corporation having its principal place of business at Horsholm, Denmark (“Santaris”), and Enzon Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at Bridgewater, New Jersey 08807 (“Enzon”). Santaris and Enzon may be referred herein individually as a “Party” or collectively, as the “Parties”.